Myosin Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for cancer and neurological disorders. The company is advancing its lead compound, MT-125, designed to treat glioblastoma by targeting a molecular nanomotor to inhibit tumor growth and invasion. The FDA has granted orphan drug designation to MT-125 for malignant gliomas, highlighting its potential to significantly improve patient outcomes.
Leadership & Board
Current Number of Employees9
Current LinkedIn Followers876
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$8M
Total Amount Raised$8M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$5M
Latest Funding Amount$5M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Myosin Therapeutics Inc had 9 employees as of April 13, 2026. The number of employees increased by 0 (0.00%) week-over-week.
9Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Myosin Therapeutics Inc had 876 followers as of April 13, 2026. The number of followers increased by 7 (0.81%) week-over-week.
876Latest Followers Count
7(0.81%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.